Treats recurrent episodes Genital herpes. ANDA 77487, held by Teva Pharms. Famciclovir.
As of Nov 16, 2026, ANDA 77487 (Famciclovir), held by Teva Pharms, was first approved by FDA on Aug 24, 2007, with 5 approved supplements and 0 published complete response letters.
Famciclovir tablets, a prodrug of penciclovir, are a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV) -Infected Adult Patients Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: Patients with first episode of genital herpes Patients with ophthalmic zoster Immunocompromised patients other than for the treatment of recurrent episodes of …
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 24, 2007 | Original application | Approved |
| Famciclovir125MG · tablet;oral | Famciclovir | Rx |
| Famciclovir250MG · tablet;oral | Famciclovir | Rx |
| Famciclovir500MG · tablet;oral | Famciclovir | Rx |
| Jul 8, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 27, 2013 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 29, 2011 | Supplement 5Labeling | Approved | None posted |
| May 9, 2011 | Supplement 4Labeling | Approved | None posted |
| Apr 29, 2009 | Supplement 3Labeling | Approved | None posted |
| Aug 24, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters